Follow us on Twitter
twitter icon@FreshPatents


Obesity patents

      

This page is updated frequently with new Obesity-related patent applications.

SALE: 320+ Obesity-related patent PDFs



new patent Substituted bridged urea analogs as sirtuin modulators
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc


new patent Vascular calcification prevention and treatment
The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc


new patent Metabolic syndrome treatment
Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc


new patent C16:1n7-palmitoleate and derivatives thereof for treating obesity, promoting weight loss, and supporting weight management
The present technology provides methods for treating obesity, promoting weight loss, and supporting weight management in a subject in need thereof. The methods include administering to the subject an effective amount of a composition comprising one or more of c16:1n7-palmitoleate, derivatives thereof, or pharmaceutically acceptable salts thereof..
Tersus Life Sciences, Llc


new patent Treatment and prevention of diabetes and obesity
Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.. .

Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
Wherein the groups r1, r2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin o-acyl transferase (goat) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity..

Substituted quinolines as pde-10 inhibitors
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.


Compounds and methods for inducing browning of white adipose tissue
The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula i, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes..
Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences


Methods for treating metabolic disorders using fgf
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies


Dermatopontin as a therapeutic for metabolic disorders
The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type i diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control..
Agency For Science, Technology And Research


Devices, solutions and methods for sample collection related applications, analysis and diagnosis

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. Saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition.
Abogen, Inc.

Mixture of purified sods of plant origin

The present invention relates to an original and specific mixture of purified superoxide dismutases (sods) of plant origin, characterised in that said mixture is essentially made up of three superoxide dismutases: a manganese superoxide dismutase, a copper and zinc superoxide dismutase and an iron superoxide dismutase provided in two isoforms, which can be obtained from an extract of the hybrid variety f1 of cucumis melo ma 7950 or the cells thereof cultured in vitro or by transfer and expression of the genes of said sods in prokaryotic or eukaryotic cells. The specific mixture according to the invention imparts to the compositions containing same a greater effectiveness in the treatment or prevention of diseases linked to inflammatory and/or oxidative stress, such as radiation-induced fibroses, cardiovascular diseases, obesity, atherosclerosis, labial herpes and myopathies, as well as in nutritional, pharmaceutical, veterinary or cosmetic uses..
Bionov

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.

Compositions and methods for treating obesity and hyperphagia

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Slim and aqua concentrate having standardized and triple salt stabilized (-)-hydroxycitric acid from garcinia cambogia extract for making concentrate and slimming water and their derived product for weight management

The present invention discloses a slim and aqueous extract of garcinia cambogia comprising (−)-hydroxycitric acid as dietary product for weight management. The present invention also discloses a process of preparation of aqueous extract wherein the garcinia cambogia fruit rinds are subjected to cold circulation to retain the phytochemical components and the aqueous extract is adjusted to neutral ph and stabilized with triple mineral salt of calcium, magnesium and potassium and decolorized using activated carbon.
Phytotech Extracts Private Limited

Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (gerd), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (gejac), infections due to bacteria that are resistant to antibiotics, including methicillin-resistant staphylococcus aureus (mrsa), clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota..
New York University

Contact area diffusion factor for quantifying fat contents of liquid

A method for determining the presence of fats in the body fluid by photographing a body fluid droplet and calculating the change of the contact area of the body fluid droplet and the contact area diffusion factor. In addition, fats may be easily detected by using a simple filming equipment where it is required to detect fats such as liposuctions, various orthopedic operations, obesity managements, etc..

Screening compound having obesity preventive or therapeutic activity

To provide a screening method for a substance having an anti-obesity action and an anti-obesity drug. A screening method including: a step for contacting a test substance and a synoviolin-gene-expressing cell; and a step for verifying the effect of the test substance on the synoviolin gene expression, or the effect thereof on synoviolin protein activity.

Bifidobacteria for treating diabetes and related conditions

This invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions..
Dupont Nutrition Biosciences Aps

Acylated glucagon analogues

The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Methods of treating an overweight or obese subject

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a metap-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject..
Zafgen, Inc.

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Drug for inhibiting adipose cell differentiation and insulin resistance

The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be yh-16, mes, myh-16, m003, m007, mz101, or the like..
Beijing Protgen Ltd.

Use of flibanserin in the treatment of obesity

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.. .
Sprout Pharmaceuticals, Inc.

Pharmaceutical composition for the treatment of obesity

The present invention relates to a layered pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts, a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients, and an intermediate inert layer that provides a time-controlled disintegration to allow separation of two drug layers and maintain their physical integrity as a single tablet. It further provides the methods for preparing the said pharmaceutical compositions for the treatment of obesity-related conditions..
Intas Pharmaceuticals Ltd.

Modulating adipose tissue and adipogenesis

The invention relates to the field of obesity and related metabolic diseases. More specifically, the invention relates to methods of reducing aggrecanase activity or antigen in mammals in order to enhance brown adipose tissue (bat) development, to promote conversion of white adipose tissue (wat) into bat in vivo, and to limit triglyceride accumulation and steatosis in the liver.
Katholieke Universiteit Leuven Ku Leuven Research & Development

Glucagon-receptor selective polypeptides and methods of use thereof

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon.
Intarcia Therapeutics Inc.

Isoquinoline derivatives as mgat2 inhibitors

The compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.. .
Merck Sharp & Dohme Corp.

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Glucagon derivatives

The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity..
Hanmi Pharm. Co., Ltd.

Partially saturated tricyclic compounds and methods of making and using same

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.
Zafgen, Inc.

Dry powder drug delivery system and methods

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity..
Mannkind Corporation

Stable pharmaceutical solution formulation of glp-1r antibody fusion protein

Disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0.01%-0.5%, and the ph value of the stable solution formulation is from 5.0 to 8.0.
Gmax Biopharm Llc.

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Amgen Inc.

1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein q, x4, x5, x6, x7, r1, r2, r3 and r8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.. .
Takeda Pharmaceutical Company Limited

Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion..
Deuterx, Llc

Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Compositions of microbiota and methods related thereto

Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as bacteroidetes, proteobacteria, firmicutes and verrucomicrobia or orders such as bacteroidales, verrucomicrobiales, clostridiales and enterobacteriales or genera such as alistipes, clostridium, escherichia, and akkermansia.
President And Fellows Of Harvard College

Anti-inflammatory and antidiabetic agents

Intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula v and formula vi and such intermediates, pharmaceutical compositions composing such compounds of the formula v and such compounds of the formula vi, and the uses of such compounds of the formula v and such compounds of the formula vi as anti-inflammatory, antiobesity and cardioprotective agents.. .

Method for treatment of hyperglycemia and hyperlipidemia

Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin k. Also provided is a method of enhancing protein expression ratio of phospho-5′ adenosine monophosphate-activated protein kinase (phospho-ampk) to total ampk in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject.

Systems and methods for enabling passage of an intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.
Obalon Therapeutics, Inc.

Method for producing hop extract

A method for producing a hop extract including filtering a hop-containing water at a temperature of 50° c. Or higher, to give a hop extract.
Suntory Holdings Limited

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders

Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.. .
The Brigham And Women's Hospital, Inc.

Co-agonists of the glucagon and glp-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 receptor/gcg receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), and obesity. .
Merck Sharp & Dohme Corp.

Glucagon derivatives with improved stability

The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pi) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents.
Hanmi Pharm. Co., Ltd.

Methods for the treatment of polycystic ovary syndrome

Polycystic ovary syndrome (pcos) is a complex and heterogeneous endocrine syndrome associated with a high risk for the development of insulin resistance, type 2 diabetes (t2d), obesity, dyslipidemia, and cardiovascular disease. There are no known therapies for the 9-18% of women afflicted with pcos.
Center For Reproducitive Medicine, Shandong Provincial Hospital, Shandong University

Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, g1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, g2a, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, g2b, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, g3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.. .
Empros Pharma Ab

Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays

This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
Senomyx, Inc.

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea analog compounds of formula (i) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as sirtuin modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Substituted bridged urea analogs as sirtuin modulators

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Nanoparticle delivery system for targeted anti-obesity treatment

A magnetic nanoparticle including a trpv1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (mnps) and a trpv1 protein agonist.
University Of Wyoming

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Anti-obesity and anti-diabetic effects of angiopoietin-like 4 (angptl4) fibrinogen-like domain

Angiopoietin-like 4 (angpt14) is a secreted protein that inhibits lipoprotein lipase (lpl) activity and promotes lipolysis in adipocytes. The present methods provides compositions comprising angptl4 fld and variants thereof of methods of using such compositions to protect a subject diet-induced obesity without affecting plasma tg levels, and, in an exemplary emobiment improve glucose homeostasis.
The Regents Of The University Of Califorina

Method of treating obesity with chlorogenic acid

The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders.

Condensed heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (i) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Biaryl derivative as gpr120 agonist

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.. .
Lg Chem, Ltd.

Hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., syndrome x), thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases

Disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.. .
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare

Implantable medical device for lubricating an artificial contacting surface

An apparatus for treating obesity of a patient having a stomach with a food cavity. The apparatus comprising a volume filling device adapted to be at least substantially invaginated by a stomach wall portion of the patient with the outer surface of the volume filling device resting against the stomach wall, such that the volume of the food cavity is reduced in size by a volume substantially exceeding the volume of the volume filling device.

Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity

The present invention provides pharmaceutical compositions formulated for direct delivery to the gi tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the gi tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition..
Circle 33 Llc

Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects.
Hanmi Science Co., Ltd

Glucagon/glp-1 agonists for the treatment of obesity

This disclosure provides glp-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.. .
Medimmune Limited

Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway

Wherein r1-r4 are as defined herein, compositions comprising an effective amount of a heteroaryl compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a heteroaryl compound to a patient in need thereof.. .

Fumagillol heterocyclic compounds and methods of making and using same

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided.
Zafgen, Inc.

Fumigillol compounds and methods of making and using same

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g.
Zafgen, Inc.

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin.
Hanmi Science Co., Ltd

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Treatment for obesity

The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds..
Sk Biopharmaceuticals Co., Ltd.

Anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

New pyrazolopyrimidine derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutical Nv

New compounds as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

New pyrazole derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv

Lkb1-ampk activators for therapeutic use in polycystic kidney disease

Compounds are provided for use in treating polycystic kidney disease (pkd) and in associated methods that include a method of modulating (e.g., activating) liver kinase b1 (lkbi); and a method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mtor). The methods may include introducing the compound in a therapeutically effective amount to a subject having pkd.
The University Of Kansas

Pyrazole compounds

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (metap2) and dipeptidyl peptidase-4 (dpp-4).
Eli Lilly And Company

Neuromodulation device

The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (csn) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the csn or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the csn or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.. .
Faculdade De CiÊncias MÉdicas Da Universidada Nova De Lisboa

A device for treating obesity and a corresponding delivery system

A device for the treatment of obesity, the device including an inflatable member positionable within the stomach of a patient and an elongated flexible sleeve positionable in the intestine of the patient and having a proximal end coupled to said inflatable member, a distal end and a side wall extending from said proximal end to said distal end and defining a lumen. The inflatable member includes an aperture for the passage of food, said aperture being in communication with the lumen of the elongated flexible sleeve..

Ovarian neuromodulation and associated systems and methods

Methods for treating polycystic ovary syndrome with therapeutic ovarian neuromodulation and associated systems and methods are disclosed herein. Polycystic ovary syndrome can be associated, for example, with a condition including at least one of oligo/amenorrhea, infertility, hirsutism, obesity, metabolic syndrome, insulin resistance, and increased cardiovascular risk profile.
Medtronic Ardian Luxembourg S.a.r.l.

Organic compositions to treat beta-enac-related diseases

The present disclosure relates to rnai agents useful in methods of treating beta-enac-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (pha1), liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a rnai agent to beta-enac.. .
Arrowhead Pharmaceuticals, Inc.

Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-lo) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g.
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center

Omefibrates for treating dyslipidemia and cardiovascular disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).. .
Jiva Pharma, Inc.

Treatment of diseases asssociated with fat accumulation

The present invention is directed to immunmodulators in the form of compositions, compounds, proteins and/or fragments with rnase activity thereof for use in the treatment of diseases associated with fat accumulation, including obesity and obesity-related disorders and metabolic disorders.. .
The Provost, Fellows, Foundation Scholars, & The Other Members Of The Board, Of The College Of The

Novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same

The disclosure relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by seq id no: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function of inhibiting the differentiation of mesenchymal stem cells into adipocytes to thereby inhibit the accumulation of adipose tissue.
Nano Intelligent Biomedical Engineering Corporation Co., Ltd.

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Novel pentadienoyl piperidine derivative and use thereof

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses.
Snu R&db Foundation

A dietary fibre composition

The invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity..
Inqpharm Group Sdn Bhd

Medical device for combating overweight or obesity in humans

Medical device for combating overweight or obesity in humans by achieving a more rapid feeling of satiety, comprising a bite raiser which can be connected to the human maxilla and/or mandible (10, 11) and which covers at least some of the occlusal surface of the masticatory teeth (13), wherein a splint (12) adapted to tooth crowns is provided for the bite raiser, which splint (12) equips at least some of the masticatory teeth (13) with an occlusal elevation (14) for reducing the size of the masticatory surface (15), which occlusal elevation (14) overlies the cusp tips (17) of a masticatory tooth (13) in order to link the bite elevation (20) to a spanning of the masticatory relief of the covered masticatory tooth (13).. .

Composition

The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) streptococcus thermophilus cbs 139100 and lactobacillus delbrueckii subsp.
Optibiotix Limited

Myristoylated leptin-related peptides and uses thereof

A pharmaceutical compound for the treatment of obesity related disorder that is a conjugate of myristic acid and a leptin-related peptide. Preferably, the leptin-related peptide is ob3 that has been d-substituted at leu-4.

Compositions and methods for lipid metabolism disorder

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected from the group consisting of liver disease, non-alcoholic fatty liver disease, hyperadiposity, dyslipidemia, hepatic steaotosis, high-fat-diet-induced lipid accumulation, high-fat-diet-induced obesity, insulin resistance, high-fat-diet-induced lipid accumulation combined with a symptom of one of inflammation and liver damage, and any combination thereof..

Methods of using fasn inhibitors

The present disclosure relates to methods of treating, preventing or ameliorating a th17- or csf1-mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a fasn inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.. .

Substituted naphthyridine and quinoline compounds as mao inhibitors

Wherein r1, r2, r3, y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting mao, and mao-b selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a cns disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.. .

Anchorless intragastric device for treating obesity

A intragastric device that contains a compressible free-floating structure and a sleeve attached thereto is provided. The device is considered to be anchorless as the sleeve is not physically attached to any portion of the gi tract.

Methods for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Alk7 binding proteins and uses thereof

This disclosure provides alk7-binding proteins such as anti-alk7 antibodies, and compositions and methods for making the alk7-binding proteins. In certain embodiments the alk7-binding proteins inhibit, or antagonize alk7 activity.
Adimab, Llc

Composition and treating metabolic disorders

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Methods for treatment of disease using galvanic vestibular stimulation

Methods are provided for treating diseases by altering body mass composition in a human subject through application of galvanic vestibular stimulation (gvs) using electrodes placed in electrical contact with the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems. The methods may be used to treat obesity-related diseases such as diabetes, hypertension, type 2 diabetes mellitus and osteoporosis.
The Regents Of The University Of California

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
The General Hospital Corporation

Phosphorylation of histones and uses thereof

Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include h2b tyr37, h4 tyr88 and tyr 51 and h3 tyr99.

Use of agents for treating fat-related disorders

Use of agents that down-regulates an amount and/or activity of abelson murine leukemia viral oncogene homolog 1 (c-abl) or checkpoint kinase 1 (chk1) in the production of a medicament for treating obesity are disclosed.. .

Aminosulfonyl compound, preparation method therefor and use thereof

Disclosed are aminosulfonyl-based compounds represented by the general formula i or tautomers, enantiomers, racemates or pharmaceutically acceptable salts thereof, a method for preparing the same, pharmaceutical compositions and uses thereof. The compounds can be used to treat epilepsy, convulsions, obesity and the like..

Composition of decreasing the accumulation of fat and use thereof

The present invention provides a natural composition of reducing weight gains and decreasing the accumulation of fat, comprising bacillus subtilis bs139 (storage id: nrrl no.b-50347) and coleus forskohlii extract. Moreover, this composition can be used in the treatment of obesity, helping them healthy reduce fat accumulation, to achieve the effect of weight loss..

Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type i, diabetes type ii, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome x..

Improved sugar-depleted fruit or vegetable juice and juice-retaining fruit or vegetable derived matter, methods of producing the same and the use thereof to maintain health and to treat and prevent medical ailments

The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l ca2+, (iii) at least about 1 g/l k+, and (iii) at least about 0.1 g/l mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g.

Growth differentiation factor 15 (gdf-15) polypeptides

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

Adeno-associated viral vectors for the gene therapy of metabolic diseases

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors.
Universitat Autonoma De Barcelona

Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor modulator (serm) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes.
Endorecherche, Inc.

System for detecting an intragastric balloon

Devices and methods for treating obesity are provided, including intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same. In one embodiment, a device includes a balloon capsule having a distal end, a catheter having a proximal end and a distal end, a connector, a light sensor, and a balloon valve.
Obalon Therapeutics, Inc.

Use of dihydrocholesterol

The use of dihydrocholesterol (dhc) in low doses of up to 50 mg per kg of body weight to treat or prevention excess weight or obesity and/or hyperlipidemia, and/or a disorders associated with any of the foregoing, and a composition comprising dhc.. .
Nestec S.a.

Vegfc production promoter

The purpose of this invention is to find a novel fragrance component effective for prevention or control of swelling, lymphedema, skin aging or obesity from the viewpoint of activation of lymph vessel function by promotion of the expression of vegfc. This invention provides a swelling improving agent, lymph vessel activator and vegfc production promoter characterized by containing one or a plurality of components selected from the group consisting of rose oxide, citronellyl acetate and niaouli oil..
Shiseido Company, Ltd.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Amgen Inc.

Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i: and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i.e., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ghsr ligand activity that is associated with weight gain and insulin resistance.
The Regents Of The University Of California

Prebiotics for reducing the risk of obesity later in life

The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of streptococcus bacteria in the gut of infants or young mammals. The infants are preferably infants in needs presenting a relatively high count of streptococcus.
Nestec S.a.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2.
Merck Sharp & Dohme Corp.

Methods, devices, and systems for obesity treatment

In one aspect, a gastric balloon structure includes multiple isolated non-concentric inflatable chambers and a valve system for introducing fluid into each chamber, where the structure assumes, upon inflating, a curved shape conforming to a natural three-dimensional kidney shape of the gastric cavity.. .
Fulfillium, Inc.

Compositions and methods for diagnosis and treatment of metabolic syndrome

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
United States Of America, As Represented By The Secretary Of The Navy

Intragastric device for treating obesity

An intragastric device including (1) a first wire mesh structure having a pre-deployment shape, a post-deployment shape greater than the pre-deployment state, and one or more openings on an upper portion of the first wire mesh structure that are configured to permit food to enter the device, (2) a second wire mesh structure having a pre-deployment shape a post-deployment shape greater than the pre-deployment state, and one or more openings on a lower portion of the second wire mesh structure that are configured to permit food to exit the device. A sleeve may be coupled to the lower portion of the wire mesh structure.
Synerz Medical, Inc.

Thienopyrroles as histone demethylase inhibitors

The present application relates to thienopyrrole derivatives, compounds of formulas (i) and (ia), wherein r, r1, r2 and r3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting kdm1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity..
Istituto Europeo Di Oncologia S.r.l.

2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)

The present invention provides compounds of formula (i) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (dat) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, tourette syndrome, angelman syndrome, attention deficit disorder (add), attention deficit hyperactivity disorder (adhd), obesity, pain, obsessive-compulsive disorder, movement disorders, cns disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.. .
Shire International Gmbh

Fgf-8 for use in treating diseases or disorders of energy homeostasis

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis.
Technische Universität München

Anti-obesity composition

(b) at least one member selected from the group consisting of sulforaphane compounds and willow extract.. .

Non-inflatable gastric implants and systems

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety.
Apollo Endosurgery Us, Inc.

2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm).
Fudan University

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases

Provided are uses of bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity-related diseases.
Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

Method of predicting obesity

The presently disclosed subject matter relates to a method for predicting increased risk of obesity on a non-obese subject. More particularly, the presently disclosed subject matter relates to a method of predicting increased risk of obesity in a non-obese subject by determining a level of neurotensin expression in a biological sample from the subject and comparing the level of neurotensin expression in the sample with a control level.
Lund University

Composition for promoting anti-diabetic and anti-obesity effects, comprising herbal extract

The present invention relates to a composition for improving anti-diabetic and anti-obesity effects, including an extract extracted from any one selected from the group consisting of lonicera japonica (lonicerae flos), scutellaria baicalensis (scutellariae radix), and houttuynia cordata (houttuyniae herba). According to the present invention, it was confirmed that co-administration of the extract of the present invention and metformin, a representative anti-diabetic drug, increases an anti-diabetic effect and reduces side effects caused by metformin, and at the same time, exhibits an anti-obesity effect by suppressing fat accumulation.
Dongguk University Gyeongju Campus Industry- Academy Cooperation Foundation

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof

This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier

Composition for preventing or treating obesity containing alpha-lipoic acid and n-acetylcysteine as active ingredients

The present invention provides a composition containing α-lipoic acid and n-acetylcysteine as active ingredients. The mixed composition of α-lipoic acid and n-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing α-lipoic acid or n-acetylcysteine..
The Asan Foundation

Cyclic polypeptides for the treatment of heart failure

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor.

Chemical compounds and use thereof for improving muscular quality

Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity.
Universite Paris 6 Pierre Et Marie Curie

N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency towards gba1, relative to known deoxynojirimycin derivatives of the same (d-gluco, l-ido or d-galacto) configuration.
Universiteit Leiden

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases

Provided are uses of bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases.
Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

Methods of treating overweight and obesity

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.. .
Orexigen Therapeutics, Inc.

Amlexanox analogs

Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.. .
The Regents Of The University Of Michigan

[7,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Swallowable capsule and stimulating incretin production within the intestinal tract

Embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Dry powder inhaler

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

Functionalized exendin-4 derivatives

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Treating various disorders using trkb agonists

Novel compounds and methods for activating the trkb receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted c5 or c6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
Emory University

Administration of an anti-obesity compound to individuals with renal impairment

The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment..
Arena Pharmaceuticals, Inc.

Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists

Phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same..
Vtv Therapeutics Llc

Compositions for treating or preventing obesity and insulin resistance disorders

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors

Feedback systems and methods enhance obstructive and other obesity treatments by presenting feedback regarding patients' actual eating. An ingestion restricting implant body can be deployed along the gastrointestinal tract.
Intrapace, Inc.

[5,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Deep brain electrode placement and stimulation based on brown adipose tissue temperature

Systems and methods for deep brain electrode placement and deep brain stimulation (dbs) for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a deep brain stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue (bat) may be monitored, e.g., via a supraclavicular temperature sensor implanted in the patient, and used to identify an optimal location of electrode stimulation which causes an increase in bat temperature.
Oregon Health & Science University

A peptide therapy to counteract insulin resistance and type 2 diabetes

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier..

Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a ucp of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance..
Industry-academic Cooperation Foundation, Yonsei University

Hsp90 inhibitors for the treatment of obesity and methods of use thereof

Hsp 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients.
The Children's Medical Center Corporation

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Apparatus for treating obesity

An apparatus for treating obesity in a human or animal mammal patient. The apparatus comprising a first volume filling device segment and a second volume filling device segment.

Method for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Method for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Preparation and use of crystalline beta-d-nicotinamide riboside

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof.
Glaxosmithkline Intellectual Property (no.2) Limited

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Agonists of the apelin receptor and methods of use thereof

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Ex vivo browning of adipose tissue therapy for reversal of obesity and type ii diabetes

Provided are methods, apparatus, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes, by administration to a subject of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues or brown adipose tissue directly converted from white adipose tissue. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue and direct browning of white adipose tissue in a bioreactor rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3d cell aggregates..
The Trustees Of Columbia University In The City Of New York

Novel glucagon analogues

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Pyrazole compounds and methods of making and using same

Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of magl, abhd6, and faah.
The Scripps Research Institute

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Solid oral formulation of fenretinide

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c.
Amgen Inc.

Oxyntomodulin analogue

Provided is an oxyntomodulin analogue. The analogue comprises gcgr and glp-1r dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions.

N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets

Provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases.
The Scripps Research Institute

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache, and pain control, asthma, angina, hypertension, depression, cold, flue and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
Merck Patentgesellschaft

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.. .
Jenrin Discovery

Method and reducing obesity

Method and apparatus for treatment of morbid obesity by placement of a series of flow reduction elements in the small intestine to induce satiety are disclosed. The flow reduction elements restrict the movement of partially digested food and reduce the flow rate through the small intestine which causes the emptying of the stomach and the duodenum to occur slower.

Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety

The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal..
University Of Copenhagen

Intragastric device with expandable portions

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Esculentin-2cha peptide and analogues thereof

The present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia..
University Of Ulster

Antidiabetic substituted heteroaryl compounds

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40.
Merck Sharp & Dohme Corp.

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension. The present invention further provides a d1 agonist with reduced d1r desensitization, a d1 agonist with a reduced β-arrestin recruitment activity relative to dopamine, a d1 agonist interacting significantly with the ser188 but not significantly with the ser202 of a d1r when binding to the d1r, a d1 agonist interacting less strongly the asp103 and interacting less strongly with the ser198 of a d1r when binding to the d1r, and their uses..

Method and instrument for treating obesity

A gastroscopic method of treating obesity of a patient using a device adapted to stretch a part of the stomach wall of said patient. The method comprising the steps of: inserting said device into the stomach of said patient through the esophagus, placing said device in contact with the stomach wall and fixating said device to the stomach wall such that said device can stretch a part of said stomach wall..

Compositions comprising cinnamaldehyde and zinc and methods of using such compositions

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.

Anti-laminin4 antibodies specific for lg1-3

The invention provides antibodies that specifically bind to the lg1-3 modules of the g domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to mcam.
Prothena Biosciences Limited

Composition of plant extract and its pharmaceutical composition and application thereof

Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs..
Caliway Biopharmaceuticals Co., Ltd.

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Technology and methods of on-board vehicle occupant accurate weighing by a simplified weighing apparatus based on weighing moderator and its applications in on-board occupant weighing systems

An on-board vehicle occupant weighing technology includes a simplified vehicle occupant weighing apparatus based on the discovered horwest effect and weighing moderator. The simplified weighing apparatus utilizes a weighing unit connected to the car seat of the vehicle occupant and a further weighing moderator, which provides convenient weighing of the foot part of the occupant's body by the same weighing unit that is connected to the car seat.

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (hpmc) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota..
New York University

Low dose topiramate/phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability.

Application of gpr45 gene

The present invention relates to the field of biotechnology, in particular to application of a gpr45 gene. The present invention discloses, for the first time, a correlation between gpr45 and obesity and also discloses that obesity may be caused if the gpr45 gene is knocked out or the expression of the gpr45 gene is reduced.

Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin a.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases.

Devices and methods for endolumenal treatment of obesity

Devices and methods for forming and securing tissue folds and elongated invaginations in stomach tissue are used as a treatment for obesity. In a first embodiment, a plurality of tissue folds is formed in the fundus region of the stomach.

Stomach-spanning gastric implants

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety.

Organic compositions to treat apoc3-related diseases

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e.g., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.. .
Arrowhead Pharmaceuticals, Inc.

Long-acting single-chain insulin analogues

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a group consisting of gly, ala, pro, or ser; and the remaining c-domain segment is successively derived from the c-domain of igf-ii (rrsr, srrsr, vsrrsr, rvsrrsr, or srvsrrsr; seq id no: 13).
Case Western Reserve University

Peptide yy (pyy) analogues

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.. .
Imperial Innovations Limited

Kv1.3 potassium channel antagonists

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection..
Conogenetix Biosciences Gmbh

Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).. .
The General Hospital Corporation

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for suppressing glucagon secretion of an sglt2 inhibitor

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor.
Astrazeneca Ab

Implantable electroacupuncture treating dyslipidemia and obesity

An exemplary method of treating obesity or dyslipidemia of a patient includes 1) generating, by an electroacupuncture device implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0.05, and 2) applying, by the electroacupuncture device in accordance with the duty cycle, the stimulation sessions to at least one of a saphenous nerve and a peroneal nerve of the patient by way of an electrode array located within the patient at an acupoint corresponding to at least one of the saphenous nerve and the peroneal nerve.. .
Valencia Technologies Corporation

Hmg1 antibody for treating inflammatory conditions

There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ards (acute respiratory distress syndrome), comprising administering an effective amount of a hmg1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of hmg1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms.
The Feinstein Institute For Medical Research

Integrated physical activity level (i-pal) measurement and tracking in adolescents and older teenagers

Described are systems that include at least one sub-system to track, measure, monitor and reward adolescents and young adults for performing daily physical activities, which include before-school, in-school, after-school, sports and activities of daily living. The system offers adolescents the opportunity to track their integrated physical activity level (i-pal) scores over their adolescent years.

Ppar modulators

The present application relates to amorfrutin analogs and uses as ppar modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low hdl cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.. .
FundaÇao Universidade De BrasÍlia

Methods for treating obesity and/or metabolic syndrome

The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
Mesoblast, Inc.

Tetrazolones as inhibitors of fatty acid synthase

Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.. .

Combination therapy for effecting weight loss and treating obesity

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies..

Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products

The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions.
The Hershey Company

Methods, devices, and systems for obesity treatment

In one aspect, a gastric balloon structure includes multiple isolated non-concentric inflatable chambers and a valve system for introducing fluid into each chamber, where the structure assumes, upon inflating, a curved shape conforming to a natural three-dimensional kidney shape of the gastric cavity.. .
Fulfillium, Inc.

Double-acylated glp-1 compounds

The invention relates to a derivative of a glp-1 peptide, which peptide comprises a first lys residue at a position corresponding to position 36 of glp-1(7-37) (seq id no:1), a second lys residue at a position corresponding to position 37 of glp-1(7-37) (seq id no: 1), and a maximum of seven amino acid changes as compared to glp-1(7-37) (seq id no: 1); which derivative comprises two protractors attached to said first and second lys residue, respectively, each via a linker; wherein the protractor is selected from: chem. 1: hooc—c6h4-0-(ch2)y—co—*, and chem.
Novo Nordisk A/s

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Astrazeneca Pharmaceuticals Lp

Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (glp-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome x..
Hyundai Pharm Co., Ltd.

Phenyl-substituted nicotinic ligands, and methods of use thereof

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, lewy body dementia, attention deficit hyperactivity disorder (adhd), parkinson's disease, huntington's disease, tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.. .
Duke University

Antiobesity agent containing walnut extract

To provide an antiobesity agent. An antiobesity agent containing an extract of walnut branches, shells, or leaves as an active ingredient..
Fms Co, Ltd.

Activation of amp-protein activated kinase by oxaloacetate compounds

The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.. .

Treatments for diabetes mellitus and obesity

Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum.

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas

Glp-1/glucagon receptor co-agonists for medical use

The present invention relates to novel glucagon derivatives which are glp-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.. .
Novo Nordisk A/s

Chimeric fibroblast growth factor 19 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.

Urea compounds and their use as enzyme inhibitors

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

Sweetness receptor antagonist

Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .

Peptide analogs for treating diseases and disorders

Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Keybioscience Ag

Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders

The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University

Cycloheptapeptide agents for treatment of cancer and obesity diseases

New anticancer and anti-obesity agents based on cyclic peptide compounds are isolated from the stem barks of maytenus variabilis (loes.) c. Y.
Hong Kong Baptist University

Treatment of obesity and obesity-related disorders by pharmalogical targeting of kv 1.3 potassium channels

Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise shk toxin or a modified shk toxin.
Kineta One, Llc

Synthetic composition for regulating satiety

The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.. .
Glycom A/s

Nitroxides for use in treating or preventing diabetes and obesity

Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes.
Mitos Pharmaceuticals, Inc.

Uses of mito-ob transgenic mice

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.

Sodium glucose co-transporter inhibitors and methods of their use

Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.. .
Lexicon Pharmaceuticals, Inc.

Maternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate maternal nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.
Nestec S.a.

Composition for inducing differentiation into beige and brown adipocytes and inducing the same

A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of ucp-1 and prdm4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment..
Gyeonggi Institute Of Science & Technology Promoti On

Formulas comprising optimised amino acid profiles

The present invention relates to infant formulas and follow-on formulas containing optimised amino acid profiles, in particular optimised amounts and/or ratios of phenylalanine. The formulas may contain intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof selected based on their ability to provide the formula with an optimised amino acid profile.
N.v. Nutricia

Compositions and methods for controlling the weight of animals

Compositions are provided comprising a balance between lysine and essential amino acids and metabolizable energy. The compositions are useful in methods to prevent or treat obesity in an animal without concomitant loss of lean muscle mass.
Hill's Pet Nutrition, Inc.



Obesity topics:
  • Hypertension
  • Inflammation
  • Nephropathy
  • Syndrome X
  • Cardiovascular
  • Endometrial
  • Polycystic Ovarian Disease
  • Prostate Cancer
  • Uterine Fibroids
  • Restenosis
  • Breast Disease
  • Dysfunctional Uterine Bleeding
  • Cardiovascular Disease
  • Aldosterone
  • Dyslipidemia


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Obesity for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Obesity with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0403

    file did exist - file did put11012

    3 - 1 - 251